Published in Blood Weekly, October 16th, 2003
In a recent study, scientists in the United States evaluated "the feasibility and activity of adding sirolimus to tacrolimus and low-dose methotrexate as graft-versus-host disease (GVHD) prophylaxis in recipients of alternative donor transplants."
"Forty-one patients with hematologic malignancies were conditioned with cyclophosphamide and total body irradiation," noted J.H. Antin and coauthors at the Dana-Farber Cancer Institute in Boston. "Marrow stem cells were from an HLA-A, -B, and -DR compatible, unrelated donor (n=26, 68%), from a 5 of 6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.